Management of In-Transit Metastatic Melanoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: melanoma develop in-transit disease (ITM)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Systemic therapies, including immune checkpoint inhibitors and targeted therapies, may also be used especially in patients with concomitant distant metastatic disease. In this article, we review the available treatment options for ITM.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
Approximately 10% of patients with melanoma develop in-transit disease (ITM).
APA
Perez MC, Zager JS (2026). Management of In-Transit Metastatic Melanoma.. Hematology/oncology clinics of North America, 40(1), 89-99. https://doi.org/10.1016/j.hoc.2025.07.008
MLA
Perez MC, et al.. "Management of In-Transit Metastatic Melanoma.." Hematology/oncology clinics of North America, vol. 40, no. 1, 2026, pp. 89-99.
PMID
41224445 ↗
Abstract 한글 요약
Approximately 10% of patients with melanoma develop in-transit disease (ITM). Although resection may be performed in patients with limited, fully resectable disease, many patients with ITM present with bulky, unresectable disease, which can pose a significant therapeutic challenge. Regional perfusion chemotherapy procedures and intralesional therapy have high response rates and can provide durable locoregional control while limiting systemic toxicity. Systemic therapies, including immune checkpoint inhibitors and targeted therapies, may also be used especially in patients with concomitant distant metastatic disease. In this article, we review the available treatment options for ITM.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.